Abrecta News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Abrecta. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Abrecta Today - Breaking & Trending Today

Novartis lung cancer drug Tabrecta gets approval

Novartis receives approval from the European Commission for Tabrecta for the treatment of non-small cell lung cancer - News - PharmaTimes ....

Juergen Wolf , European Union , European Commission For Tabrecta , European Commission , University Hospital Cologne , Medicinal Products , Human Use , European Medicines Agency , Integrated Oncology , Lung Cancer ,

Novartis Receives Positive CHMP Opinion For Tabrecta For Patients With METex14 Lung Cancer

BASEL (dpa-AFX) - Novartis (NVS) said Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion and recommended granting ....

European Medicines Agency , Committee For Medicinal Products Human Use , Medicinal Products , Human Use ,

Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer

The positive opinion from the CHMP is based on Phase 2 GEOMETRY mono-1 study showing an overall response rate (ORR) of 51.6% in a cohort evaluating second-line patients only and 44% in all previously-treated ....

United States , Juergen Wolf , Catalina Loveman , Peter Langmuir , Le Mouhaer , Christine Chiou , American Society Of Clinical Oncology , European Commission , Group Vice , University Hospital Cologne , Exchange Commission , European Union , European Medicines Agency , Committee For Medicinal Products Human Use , Medicinal Products , Human Use , Group Vice President , Oncology Targeted Therapies , Clinical Oncology , Annual Meeting , Integrated Oncology , Blinded Independent Review Committee , Disease Control Rate , Looking Statements ,

Novartis Pharma AG: Novartis receives positive CHMP opinion for Tabrecta for patients with METex14 advanced non-small cell lung cancer

Opinion based on Phase II GEOMETRY mono-1 study showing an overall response rate (ORR) of 51.6% in a cohort evaluating second-line patients only and 44% in all previously-treated patients with advanced ....

United States , Juergen Wolf , Isabella Zinck , Le Mouhaer , Veronique Boissonnas , Nicole Zinsli Somm , Samir Shah , Parag Mahanti , Julie Masow , Sloan Simpson , Alina Levchuk , Global Oncology Communications , American Society Of Clinical Oncology , European Commission , World Health Organization , University Hospital Cologne , Novartis Us External Communications , Novartis External Communications , Exchange Commission , Innovative Medicines International , European Union , European Medicines Agency , Committee For Medicinal Products Human Use , American Cancer Society , Medicinal Products , Human Use ,

Novartis Pharma AG: Novartis announces Tabrecta first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

Tabrecta (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data1,2 Tabrecta achieved ....

United States , Hong Kong , Juergen Wolf , Isabella Zinck , Jeff Legos , Thomas Hungerbuehler , Chan Al , Biochim Biophys Acta , Samir Shah , Mary Curtin Creaser , Julie Masow , Sloan Simpson , American Joint Committee On Cancer , American Society Of Clinical Oncology , University Hospital Cologne , Novartis External Communications , National Comprehensive Cancer Network Guidelines , American Cancer Society , Global Oncology Communications , Study Of Capmatinib , Virtual Scientific Program , Drug Administration , Foundation Medicine Inc , World Health Organization , Novartis Us External Communications , Exchange Commission ,